Zentalis Pharmaceuticals Inc (ZNTL)

$2.73 +0.02 (0.74%)
Market Cap 195.80M
Revenue (ttm) 67.43M
Net Income (ttm) -165.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -245.94%
Debt to Equity Ratio 0.00
Volume 469,800
Avg Vol 1,462,492
Day's Range N/A - N/A
Shares Out 72.25M
Stochastic %K 59%
Beta 1.71
Analysts Sell
Price Target $5.31

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 433 3791
Address:
10275 Science Center Dr., Suite 200, San Diego, United States
StockNews_Live
StockNews_Live Mar. 17 at 8:39 PM
$ZNTL 🎯 STOCK NEWS ALERT 💵 Price: $2.74 (+0.74%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Zentalis Pharmaceuticals announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company will present data on azenosertib ADC combinations… 📎 https://stocknews.live/news/ZNTL/zentalis-pharmaceuticals-to-present-two-posters-at-the-american-emnewvru1yii.html
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 13 at 1:59 PM
$ZNTL RSI: 58.66, MACD: 0.0857 Vol: 0.22, MA20: 2.51, MA50: 2.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
lucabrix
lucabrix Mar. 11 at 8:44 PM
$ZNTL nice AH!!
0 · Reply
THE_MADMAN
THE_MADMAN Mar. 11 at 11:40 AM
$ZNTL anyone here?
0 · Reply
StockScanners
StockScanners Mar. 11 at 7:03 AM
$ZNTL keep watch if this holds above 3.04
0 · Reply
lucabrix
lucabrix Mar. 10 at 9:01 PM
$ZNTL Volume is getting hot, way to run!
0 · Reply
Snackdaddy
Snackdaddy Mar. 10 at 7:14 PM
$ZNTL nice two day pump. dump now? or one more day?
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 7:00 PM
$ZNTL Not a bad session at all for momentum traders 🙌. Price moved cleanly higher. Buyers stayed in control.
1 · Reply
lucabrix
lucabrix Mar. 10 at 4:19 PM
$ZNTL Right!!
0 · Reply
GangsterX
GangsterX Mar. 10 at 2:28 PM
$ZNTL this stock is good to swing when i called it at 2.20. I think it can run up to 4... just in/out like junping jack the u are okay...
0 · Reply
Latest News on ZNTL
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 17, 2026, 4:30 PM EDT - 2 hours ago

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 27 days ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Feb 3, 2026, 4:05 PM EST - 6 weeks ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Jan 6, 2026, 8:00 AM EST - 2 months ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

Dec 9, 2025, 2:07 PM EST - 3 months ago

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Nov 10, 2025, 4:05 PM EST - 4 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 5:25 PM EST - 4 months ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 5 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:27 PM EDT - 6 months ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Aug 26, 2025, 4:05 PM EDT - 7 months ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 5:00 PM EDT - 9 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 4:05 PM EDT - 10 months ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 28, 2025, 8:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 15, 2025, 11:25 AM EDT - 1 year ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Key Management Appointments

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 9:00 AM EDT - 1 year ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 4:00 PM EDT - 1 year ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

StockNews_Live
StockNews_Live Mar. 17 at 8:39 PM
$ZNTL 🎯 STOCK NEWS ALERT 💵 Price: $2.74 (+0.74%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Zentalis Pharmaceuticals announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company will present data on azenosertib ADC combinations… 📎 https://stocknews.live/news/ZNTL/zentalis-pharmaceuticals-to-present-two-posters-at-the-american-emnewvru1yii.html
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 13 at 1:59 PM
$ZNTL RSI: 58.66, MACD: 0.0857 Vol: 0.22, MA20: 2.51, MA50: 2.58 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
lucabrix
lucabrix Mar. 11 at 8:44 PM
$ZNTL nice AH!!
0 · Reply
THE_MADMAN
THE_MADMAN Mar. 11 at 11:40 AM
$ZNTL anyone here?
0 · Reply
StockScanners
StockScanners Mar. 11 at 7:03 AM
$ZNTL keep watch if this holds above 3.04
0 · Reply
lucabrix
lucabrix Mar. 10 at 9:01 PM
$ZNTL Volume is getting hot, way to run!
0 · Reply
Snackdaddy
Snackdaddy Mar. 10 at 7:14 PM
$ZNTL nice two day pump. dump now? or one more day?
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 7:00 PM
$ZNTL Not a bad session at all for momentum traders 🙌. Price moved cleanly higher. Buyers stayed in control.
1 · Reply
lucabrix
lucabrix Mar. 10 at 4:19 PM
$ZNTL Right!!
0 · Reply
GangsterX
GangsterX Mar. 10 at 2:28 PM
$ZNTL this stock is good to swing when i called it at 2.20. I think it can run up to 4... just in/out like junping jack the u are okay...
0 · Reply
lucabrix
lucabrix Mar. 9 at 4:14 PM
$ZNTL I know somthing! Time to buy!!!
1 · Reply
Gaben
Gaben Mar. 9 at 3:05 PM
$ZNTL Take it, take it. Someone knows something.
0 · Reply
GangsterX
GangsterX Mar. 6 at 4:05 PM
$ZNTL this stock is good to "Swing" i dont think it drops under 2. Dont ask me if i have a position or not
1 · Reply
Snackdaddy
Snackdaddy Mar. 5 at 5:35 PM
$ZNTL there will be a filing in a fee days that an insider dumped. $1.60 coming by end of May
3 · Reply
Sillyspuh
Sillyspuh Mar. 4 at 7:30 PM
$ZNTL Good to see some asset managers getting back in the game investing in zntl: https://ir.zentalis.com/node/11036/html
2 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 4:07 AM
$ZNTL Current Stock Price: $2.38 Contracts to trade: $2.5 ZNTL Mar 20 2026 Call Entry: $0.18 Exit: $0.26 ROI: 46% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 3:05 AM
$ZNTL RSI: 48.78, MACD: -0.0053 Vol: 0.12, MA20: 2.44, MA50: 2.38 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Broview
Broview Mar. 1 at 2:08 AM
$ZNTL consider as real option trade?
0 · Reply
Snackdaddy
Snackdaddy Feb. 24 at 10:19 PM
$ZNTL this could possibly be the 2026 version of 2025 KOD. KOd from $2 to $32 now $27 awaiting bigbnews next month.
2 · Reply
lucabrix
lucabrix Feb. 19 at 9:34 PM
$ZNTL Here we are!!!
2 · Reply
topstockalerts
topstockalerts Feb. 19 at 6:58 PM
$ZNTL Solid bounce off recent lows. Buyers stepped in with conviction. That usually signals a trend change 🔄.
2 · Reply
Parobull
Parobull Feb. 19 at 3:11 AM
AGAE small cap math is simple tiny float cap, strong cash position, real partnership backing, bullish technical cross forming. Break.40 and momentum could carry this toward .50+. and then 1+ just like OLB $ENTA $VNDA $ZNTL $SANA
0 · Reply